A new study in Rheumatology exhibits timeline, as well as cautionary tale, concerning the etiology and treatment of chronic diseases. In this instance, osteoporosis, a disease characterized by low bone strength and fractures that occur with very low-impact loads, has experienced many changes over the past 20 years and we should expect to see many more in the future.
Prior to 1990, there was little activity in the field: although there were some small studies with sodium fluoride, they set the field back because these compounds improved bone mass but increased bone fragility and fractures. While osteoporosis, or bone fragility, was generally accepted to be part of the normal process of aging in post-menopausal women, an osteoporotic fracture diagnosed the disease, unfortunately at a very advanced stage. Until the development of DPA followed by dual-energy X-ray absorptiometry (DEXA), there was no method to determine an individual's risk of an osteoporotic fracture before the event. However, in 1992, T-scores became a way to identify individuals who would, over time, be at increased risk of osteoporotic fractures. This ability to identify individuals at risk for fractures prior to their occurrence by DEXA, coupled in 1990 with the first studies to find a reduction in incident vertebral fractures with the bisphosphonate etidronate, administered for 2 weeks every 3 months, followed by the approval of the bisphosphonate alendronate in the USA in 1995, really jump-started the field. Post- and pre-menopausal women and men obtained BMD scans, and, based on a T-score of −1 or below at the lumbar spine or hip, were started on this anti-resorptive agent indefinitely. Over time, other bisphosphonates were approved, initially daily treatment, then weekly, then monthly, followed by i.v. therapies, first every 3 months and now annually.
The past decade also saw the approval of the first 'anabolic' or bone-building agent that could increase bone strength by increasing both bone formation and bone resorption. The anabolic agent teriparatide allowed bone strength to increase by adding bone to existing trabeculae. However, with the discontinuation of teriparatide, the new bone would be rapidly lost; the addition of an anti-resorptive agent maintained or even increased BMD.
In addition, the Women's Health Initiative Study reported that HRT, while effective in reducing hip fractures and gastrointestinal cancer, had risks of cardiovascular events that outweighed the benefits. This dramatically changed how physicians treated post-menopausal women, especially in the prevention of estrogen-deficient bone loss in early menopause. However, the number of new, generally non-hormonal medications to treat or prevent osteoporosis kept clinicians busy learning the biology of bone metabolism, and most became very good at identifying and prescribing for patients who should be treated for osteoporosis.
One drug company-sponsored study suggested to clinicians that after 5 years an anti-resorptive agent could be discontinued, but no guidelines were produced on how to monitor these subjects after therapy was discontinued: this has been left to clinicians to figure out. In the past 3 years, quite unexpectedly, a number of series of cases of subtrochanteric or atypical fractures have been reported in women treated with bisphosphonates for a number of years. The reports from multiple centers are strikingly similar. The American Society of Bone and Mineral Research convened a task force to investigate the problem and the Food and Drug Administration made recommendations. One of the major risk factors appears to be the length of time a patient has taken the bisphophonate. While pharmaceutical manufacturers were successful in convincing clinicians that these medications would improve patients' bone strength, no guidance was provided on the length of time that the medication should be prescribed. The Phase III studies carried out to seek FDA approval of the bisphosphonates were only 3 years in duration. However, many of the patients' subtrochanteric fractures had been treated with these medications for much longer. So we have learnt a lesson in the treatment of osteoporosis: 3 years is effective, and much longer might cause some harm. This story is not finished...
Bonnie - the effectiveness is highly questionable as it is, but the harm is evident. I have seen it too many times. In addition, the key marker that clinicians use for assessing osteoporosis risk, T-scores, are highly questionable as well.
...The use of the T-score to identify patients who might be at risk for osteoporotic fractures, and using a T-score of −1 or less as a threshold to treat patients with bone-active medications, was not satisfying.
While medications can improve bone strength, a patient generally has to fall to suffer a hip fracture. Clinicians, almost as a reflex, institute medications to treat osteoporosis, and fail to do an assessment of a patient's risk of falling. A thorough evaluation for osteoporosis and fracture risk includes: a review of the patient's medications for sedatives/hypnotics that impair balance and increase fall risk; a physical examination to determine muscle strength and balance; and a review of laboratory tests including hemoglobin, hematocrit and electrolytes. Going forward, the authors of this study would like to believe clinicians will be more thorough in their assessment of fracture risk both with FRAX and an assessment of fall risk, and interventions may be both pharmacological and non-pharmacological. We have come a long way, but we have much left to do.
Bonnie - without saying it, the authors of this study are hinting that osteoporosis is the perfect example of how drug companies concocted a disease in order to open up a new market for themselves. The one prescription medication the authors ignored, which is the cheapest, safest, and has had good success, is salmon calcitonin. Calcitonin works on specifically on bone resorption, not bone formation, which bisphosphonates perform in irregular, brittle fashion. The following study has even more exciting news regarding a new delivery system for calcitonin.
Oral recombinant salmon calcitonin tablets (200 mg daily) are more effective at improving lumbar spine bone mineral density (BMD) after 48 weeks than placebo or a nasal formulation of the hormone, according to the results of a phase 3 multinational double-blind trial presented here at the American Society for Bone and Mineral Research 2011 Annual Meeting. Dual-emission X-ray absorptiometry scans showed the oral formulation to be better than the nasal formulation at increasing BMD of the lumbar spine. At the exit visit, fasting carboxy-terminal collagen crosslink (CTx) serum levels, indicating bone resorption, decreased by 29.9% in the oral groups.
No comments:
Post a Comment